ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 880

Tofacitinib Treatment in Patients with Psoriatic Arthritis and Rates of Radiologic Progression According to Baseline CRP Levels: Results from a Phase 3 Clinical Study

Désirée van der Heijde1, Dafna D Gladman2, Oliver FitzGerald3, Arthur Kavanaugh4, Daniela Graham5, Cunshan Wang5 and Lara Fallon6, 1Leiden University Medical Center, Leiden, Netherlands, 2Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland, 4University of California San Diego School of Medicine, La Jolla, San Diego, CA, 5Pfizer Inc, Groton, CT, 6Pfizer Canada, Montreal, QC, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Psoriatic arthritis, tofacitinib and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment I

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). Here, we evaluate radiographic progression in PsA patients (pts) treated with tofacitinib, using data from a global, 12-month, placebo- and active-controlled, parallel-group Phase 3 study. Pts had an inadequate response to ≥1 conventional synthetic disease-modifying antirheumatic drug, and were tumor necrosis factor inhibitor‑naïve (OPAL Broaden; NCT01877668).

Methods: Pts were randomized to receive oral tofacitinib 5 mg twice daily (BID), tofacitinib 10 mg BID, adalimumab (ADA) 40 mg subcutaneous once every 2 weeks, or placebo (PBO). Pts who initially received PBO advanced to tofacitinib 5 or 10 mg BID at Month (M)3. Radiographs of the hands and feet at baseline (BL) and M12 were scored independently by 2 assessors using the van der Heijde-modified Total Sharp Score for PsA (mTSS; range 0–528);1 average scores were used. For radiographs missing at M12, mTSS was calculated by linear extrapolation from an earlier mTSS. Change from BL in mTSS, erosion and joint space narrowing (JSN) was reported for all pts and pts grouped by BL C‑reactive protein (CRP) >2.87 mg/L or ≤2.87 mg/L. The proportion of pts with radiographic non-progression (defined as either an increase from BL in mTSS ≤0.5 or ≤0 and less than the smallest detectable change [SDC; ≤0.66 derived from this trial]) at M12 are reported for all pts.

Results: Treatment groups were comparable for demographics and BL characteristics (Table 1). Pts in all groups demonstrated minimal changes from BL in mTSS, erosion, and JSN at M12 (Table 2). Change from BL was similar in pts with CRP >2.87 mg/L or ≤2.87 mg/L. Radiographic non-progression at M12 using any threshold was observed in >90% of pts in all groups. At M12, 95.9%, 94.9%, and 97.9% of pts receiving tofacitinib 5 mg BID, tofacitinib 10 mg BID, and ADA, respectively, were non-progressors based on radiographic changes less than the SDC in mTSS.

Conclusion: Pts with PsA receiving tofacitinib showed minimal mean changes in mTSS at M12, regardless of whether BL CRP level was >2.87 mg/L or ≤2.87 mg/L. At M12, >90% of pts who received tofacitinib or ADA met all radiographic non-progression criteria.

  1. van der Heijde et al. Ann Rheum Dis 2005;64 Suppl 2:ii61-4.


 


Disclosure: D. van der Heijde, AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer Inc, Regeneron, Roche, Sanofi, Takeda, UCB, 5,Imaging Rheumatology bv., 9; D. D. Gladman, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, UCB, 2,AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, UCB, 5; O. FitzGerald, AbbVie, Bristol-Myers Squibb, Novartis, Pfizer Inc, 2,Amgen, Celgene, Janssen, Lilly, 5; A. Kavanaugh, Pfizer Inc, 9; D. Graham, Pfizer Inc, 1,Pfizer Inc, 3; C. Wang, Pfizer Inc, 1,Pfizer Inc, 3; L. Fallon, Pfizer Inc, 1,Pfizer Inc, 3.

To cite this abstract in AMA style:

van der Heijde D, Gladman DD, FitzGerald O, Kavanaugh A, Graham D, Wang C, Fallon L. Tofacitinib Treatment in Patients with Psoriatic Arthritis and Rates of Radiologic Progression According to Baseline CRP Levels: Results from a Phase 3 Clinical Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/tofacitinib-treatment-in-patients-with-psoriatic-arthritis-and-rates-of-radiologic-progression-according-to-baseline-crp-levels-results-from-a-phase-3-clinical-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tofacitinib-treatment-in-patients-with-psoriatic-arthritis-and-rates-of-radiologic-progression-according-to-baseline-crp-levels-results-from-a-phase-3-clinical-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology